Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell RNA sequencing identifies Endothelial derived HBEGF promoting Pancreatic Beta Cell Proliferation via EGFR-Kmt5a-H4K20me Pathway [bulk RNA-seq]

ABSTRACT: Single-cell RNA sequencing identifies Endothelial derived HBEGF promoting Pancreatic Beta Cell Proliferation via EGFR-Kmt5a-H4K20me Pathway [bulk RNA-seq]

PROVIDER: PRJNA1169191 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30891905_1.fastq.gz	Fastqsanger.gz
	SRR30891905_2.fastq.gz	Fastqsanger.gz
	SRR30891906_1.fastq.gz	Fastqsanger.gz
	SRR30891906_2.fastq.gz	Fastqsanger.gz
	SRR30891907_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Single-cell RNA sequencing identifies Endothelial derived HBEGF promoting Pancreatic Beta Cell Proliferation via EGFR-Kmt5a-H4K20me Pathway [scRNA-seq]

Project description:Single-cell RNA sequencing identifies Endothelial derived HBEGF promoting Pancreatic Beta Cell Proliferation via EGFR-Kmt5a-H4K20me Pathway [scRNA-seq]

| PRJNA1169192 | ENA

KMT5A-Mediated Methylation of IRF3 Promotes Tumor Progression through Immune Suppression

Project description:Lysine methylation is a critical post-translational modification (PTM) involved in diverse physiological and pathological processes. Interferon regulatory factor 3 (IRF3) plays a pivotal role in antitumor immunity; however, the regulatory mechanisms and functional impact of IRF3 methylation within the tumor microenvironment remain incompletely understood. This study demonstrates that monomethylation of IRF3 at lysine 193 (K193) suppresses its phosphorylation-dependent activation. Mass spectrometry-based protein interactome analysis identified lysine methyltransferase 5A (KMT5A) as the key enzyme responsible for IRF3 K193 monomethylation. In colorectal cancer (CRC), aberrantly high expression of KMT5A impaired in vivo antitumor immune responses. Mechanistically, KMT5A catalyzes IRF3 monomethylation at K193, which impedes IRF3 phosphorylation and subsequent activation, thereby suppressing the production of type I interferons (IFN-I). Collectively, these findings elucidate KMT5A-mediated IRF3 K193 methylation as a critical regulatory axis promoting tumor immune evasion and progression. Furthermore, IRF3 K193 methylation represents a promising therapeutic target for CRC intervention.

2025-12-03 | GSE312287 | GEO

Transcriptomic analysis of KMT5A-knockout healthy volunteer peripheral blood CD8+ T cells under activated conditions

Project description:This study aims to investigate the role of Lysine Methyltransferase 5A (KMT5A, also known as SETD8) in CD8+ T cell biology. CD8+ T cells were isolated from healthy volunteer PBMCs using magnetic bead-based negative selection. Isolated cells were subjected to CRISPR-Cas9 mediated gene editing targeting KMT5A (KMT5A-KO group) or a non-targeting control guide RNA (control group, CTRL) via ribonucleoprotein (RNP) complex electroporation. Cells were harvested at 72 hours post-electroporation for RNA extraction. RNA sequencing (RNA-seq) libraries were constructed using the Illumina TruSeq Stranded mRNA kit and sequenced on an Illumina platform to generate paired-end reads. Transcriptome profiles of KMT5A-KO CD8+ T cells were compared to those of CTRL cells to identify differentially expressed genes (DEGs) and elucidate potential pathways regulated by KMT5A in this cell type.

2025-12-02 | GSE304753 | GEO

Identification of KMT5A regulated genes in prostate cancer

Project description:The methyltransferase, KMT5A, is suggested as an oncogene in prostate cancer but the mechanisms underlying its oncogenic properties are poorly understood. This study uncovers genes and cellular pathways which are regulated by KMT5A in LNCaP-AI cells, a model of androgen independence.

2023-05-26 | GSE233350 | GEO

EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma

Project description:Co-amplification of EGFR and EGFRvIII, a tumor-specific truncation mutant of EGFR, represent hallmark genetic lesions in glioblastoma. We report that EGFR and EGFRvIII stimulate the innate immune defense receptor Toll-like Receptor 2 (TLR2); and that knockdown of TLR2 led to a dramatic survival advantage in glioblastoma xenografts. EGFR and EGFRvIII activated TLR2 in a ligand-independent manner, promoting tumor growth and immune evasion. We show that EGFR and EGFRvIII cooperate to activate the Rho-associated protein kinase ROCK2, modulating malignant progression both by activating TLR2 and WNT signaling, and through remodeling the tumor microenvironment.

2024-11-26 | PXD034586 | Pride

Single-cell RNA sequencing identifies Endothelial derived HBEGF promoting Pancreatic Beta Cell Proliferation via EGFR-Kmt5a-H4K20me Pathway [bulk RNA-seq]

Project description:Pancreatic beta cells mass is dynamically regulated in response to increased physiological demands during pregnancy. We used RNA sequencing (RNA-seq) to analyze the diversity and character of islets cells in pancreas.

2024-12-10 | GSE278861 | GEO

Single-cell RNA sequencing identifies Endothelial derived HBEGF promoting Pancreatic Beta Cell Proliferation via EGFR-Kmt5a-H4K20me Pathway [scRNA-seq]

Project description:Pancreatic beta cells mass is dynamically regulated in response to increased physiological demands during pregnancy. We used single-cell RNA sequencing (scRNA-seq) to analyze the diversity and character of islets cells in pancreas.

2024-12-10 | GSE278860 | GEO

EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma

Project description:EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma

| PRJNA875052 | ENA

Hepatocyte-specific epidermal growth factor receptor (EGFR) deletion attenuates acetaminophen-induced liver injury in mice [RNA-seq AVITI]

Project description:Epidermal growth factor receptor (EGFR) is mostly known for its proliferative role in liver. Our earlier investigations indicated a paradoxical cell-death promoting facet of EGFR in acetaminophen (APAP)-induced liver injury (AILI) model. The current study investigates this unexpected role of EGFR in promoting AILI using a hepatocyte-specific EGFR deletion mouse model. Hepatocyte-specific EGFR-deficient mice were generated by administering AAV8-TBG-CRE in EGFRfl/fl mice and were subsequently treated with a severely toxic dose (500 mg/kg) of APAP. Liver injury, regeneration and associated signaling pathways were assessed at different time intervals. EGFR deletion significantly attenuated the progression of liver injury (beyond 12hr post-APAP) without altering early liver injury (up to 6 hr) following APAP overdose. Consistently, the key injury initiating events such as APAP-protein adducts formation and early JNK activation remained intact in EGFR-deficient mice. However, EGFR deletion restricted prolonged JNK activation and its mitochondrial translocation, resulting in reduced propagation of mitochondrial damage and release of cell death drivers. Further, the replenishment of antioxidant glutathione (GSH), which is known to limit the progression of liver injury, was strikingly faster in EGFR-deficient mice. RNA-seq analysis and consequent validation revealed marked upregulation of autophagy and its transcriptional regulator TFEB, a key response to remove damaged mitochondria, in EGFR-deficient mice. Paradoxically, EGFR deletion also promoted compensatory liver proliferative response secondary to decreased progression of liver injury. Overall, hepatocyte-specific EGFR deletion halted the progression of AILI. Our study established an unexpected death promoting function of EGFR in AILI progression, which has wide implications in liver biology.

2025-11-13 | GSE309115 | GEO

Hepatocyte-specific epidermal growth factor receptor (EGFR) deletion attenuates acetaminophen-induced liver injury in mice [RNA-seq Illumina]

2025-11-13 | GSE309117 | GEO